{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:49:21Z","timestamp":1765356561112,"version":"3.40.5"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis is a chronic, recurrent, inflammatory, and proliferative skin disease. Its etiology has not yet been fully assessed, but undoubtedly it is a multifaceted disease. The key role in its pathomechanism is played by genetic, immunologic, and environmental factors and stress. If traditional methods of psoriasis treatment (phototherapy, methotrexate, retinoids, cyclosporine A) fail, we reach for the following biopharmaceuticals \u2013 infliximab, etanercept, adalimumab, or ustekinumab. However, genetic engineering progress discovers new possibilities \u2013 the pending clinical trials involve <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201023 antagonists, <jats:styled-content style=\"fixed-case\">PDE<\/jats:styled-content>4 and \u20103 and \u20101. Psoriasis etiopathogenesis mainly involves the <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A, <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017F, and <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A\/F subtypes, which affect the keratinocytes. The biological therapy molecularly oriented with the antagonists of interleukin 17 is based mainly on the influence onto the cytokine in the manner that prevents it from binding with the receptor. Three biopharmaceuticals are currently under third phase studies: two fully humanized antibodies neutralizing <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017 \u2013 ixekizumab and secukinumab, and one human monoclonal antibody, brodalumab. The below work will be devoted to the analysis of possible undesirable symptoms, which were observed during the studies. We will try to review the latest literature concerning the most important clinical trials conducted in many centers.<\/jats:p>","DOI":"10.1111\/ijd.14509","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T10:58:34Z","timestamp":1560423514000},"page":"1360-1365","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Are new variants of psoriasis therapy (<scp>IL<\/scp>\u201017 inhibitors) safe?"],"prefix":"10.1111","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0501-7592","authenticated-orcid":false,"given":"Dominika","family":"Wcis\u0142o\u2010Dziadecka","sequence":"first","affiliation":[{"name":"Department of Cosmetology School of Pharmacy with Division of Laboratory Medicine in Sosnowiec Medical University of Silesia Sosnowiec Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Ka\u017amierczak","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology School of Pharmacy with Division of Laboratory Medicine in Sosnowiec Silesian Medical University Sosnowiec Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beniamin","family":"Grabarek","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology School of Pharmacy with Division of Laboratory Medicine in Sosnowiec Silesian Medical University Sosnowiec Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martyna","family":"Zbiciak\u2010Nylec","sequence":"additional","affiliation":[{"name":"Department of Dermatology Andrzej Miel\u0119cki Memorial Independent Public Clinical Hospital in Katowice Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligia","family":"Brzezi\u0144ska\u2010Wcis\u0142o","sequence":"additional","affiliation":[{"name":"Chair and Department of Dermatology School of Medicine in Katowice Medical University of Silesia Katowice Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"69","article-title":"Psoriasis biological treatment in Poland","volume":"11","author":"Paluchowska E","year":"2013","journal-title":"Zdrowie Publiczne i Zarz\u0105dzanie"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.5604\/17322693.1009980"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.12703\/P6-4"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/187153012802002901"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-017-9411-6"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0658-y"},{"key":"e_1_2_5_8_1","first-page":"13","article-title":"Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?","volume":"27","author":"Barrea L","year":"2015","journal-title":"J Transl Med"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2013.25.4.440"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph13070743"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2013.07.014"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0064-x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-014-1455-9"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03325637"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.879093"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.806483"},{"key":"e_1_2_5_18_1","first-page":"155","article-title":"New systemic therapies for psoriasis","volume":"95","author":"Mansouri Y","year":"2015","journal-title":"Cutis"},{"key":"e_1_2_5_19_1","first-page":"1","article-title":"Novel systemic therapies for the treatment of psoriasis","volume":"7","author":"Tan KW","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.033"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.058"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479163"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.10.009"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.14509","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.14509","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.14509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T18:45:30Z","timestamp":1694198730000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.14509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/ijd.14509"],"URL":"https:\/\/doi.org\/10.1111\/ijd.14509","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"type":"print","value":"0011-9059"},{"type":"electronic","value":"1365-4632"}],"subject":[],"published":{"date-parts":[[2019,6,13]]},"assertion":[{"value":"2018-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}